6 results about "Fulvestrant" patented technology

This invention discloses a nanomedicine and its application in the four-modal synergistic treatment of ER+ breast cancer, encompassing gas therapy, photothermal therapy, photodynamic therapy, and combined therapy, relating to the fields of biotechnology and new medicine. This nanomedicine uses an amphiphilic polymer as a carrier and organic compounds and photosensitizers as drug loading agents. Through the synergistic effects of four modes—photothermal, photodynamic, gas therapy, and combined therapy—it effectively inhibits the growth and metastasis of breast cancer cells. The amphiphilic polymer, based on PHHM-ADT, is modified with hydrogen sulfide gas as a donor, and its amphiphilicity allows for spontaneous assembly into nanoscale hollow, regular spheres. Utilizing the high permeability and retention effect (EPR effect) at the tumor site, it achieves efficient drug accumulation in tumor tissue. The prodrug PSF couples fulvestrant and pabuxiparin via disulfide bonds, and the photosensitizer IR808 integrates photothermal and photodynamic therapy. The synergistic effect of multiple mechanisms of action enhances the therapeutic effect.

This invention belongs to the fields of pharmaceutical chemistry and photocatalysis, and discloses a method for the photocatalytic synthesis of fulvestrant intermediates using pentafluorochloroethane and its applications. The method uses allyl ester compounds as substrates and pentafluorochloroethane (Freon-115) as a perfluoroalkylating agent. Under visible light irradiation, a specific photocatalytic redox system is constructed, and a boron-containing activator is introduced to synergistically activate the inert C-Cl bond, achieving the pentafluoroethylation-hydrogenation reaction of allyl esters to efficiently synthesize pentafluoropentyl benzoate. The method of this invention features mild reaction conditions, avoiding the use of highly toxic tin reagents in traditional processes, and simultaneously achieving high-value utilization of industrial waste gas Freon-115, demonstrating significant atom economy and promising industrial application prospects.

This invention discloses the use of AKT inhibitors in the manufacture of drugs for the prevention or treatment of breast cancer. In particular, it provides the combination of an AKT inhibitor and fulvestrant in the manufacture of drugs for the prevention or treatment of breast cancer. The combination of an AKT inhibitor and fulvestrant can effectively inhibit the proliferation and colonization of breast cancer cells. The combination is clearly more effective than monotherapy, exhibits additive or synergistic effects, has lower toxicity and side effects to normal cells, is safer, and provides a more effective method for treating breast cancer, thus having significant clinical value.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The application belongs to the technical field of high polymer materials, and discloses a supramolecular hydrogel carrier, a supramolecular hydrogel loaded with fulvestrant and a preparation method and application thereof. Raw materials of the supramolecular hydrogel carrier are composed of carboxyl-modified PF127, amino-modified β-cyclodextrin, (ferrocenemethyl) trimethylammonium bromide, MXene and a residual amount of deionized water. The carboxyl-modified PF127 is a substance for forming a network structure of the supramolecular hydrogel carrier. The supramolecular hydrogel can be used as a carrier of fulvestrant for treating tumors, has the properties of being injectable, temperature-sensitive and having a porous structure, and is helpful for killing tumor cells.

A combination therapy comprising enoxacin, palbociclib, and fulvestrant is provided, along with a method for treating locally advanced or metastatic breast cancer with PIC3CA mutations, hormone receptor-positive (HR+), and HER2-negative (HER2-), the method comprising administering therapeutically effective amounts of enoxacin, palbociclib, and fulvestrant. The combination therapy produced statistically significant and clinically meaningful improvements in comparable patients compared to administration of palbociclib and fulvestrant alone.